In some tissue samples, we were able to detect SGLT2 immunoreactivity at or near plasma membranes, and this suggests that endothelial SGLT2 participates in Me4FDG uptake across the blood-tumor barrier. The gene discussed is SLC5A2; the disease is neoplasm.